HAYWARD, Calif. — Impax Labs on Wednesday announced that it has acquired from Actavis two generic products for cash consideration. Financial terms of the agreement were not disclosed.
The acquisition includes one product marketed under an abbreviated new drug application — Ursodiol tablet — and one approved aNDA that is not yet marketed — Lamotrigine orally disintegrating tablet.
"The acquisition of these products from Actavis is just one example of our ongoing strategy of expanding our product offerings and portfolio with strategic business development projects," said Fred Wilkinson, president and CEO Impax Laboratories. "Successful implementation of our M&A and business development activities should complement our internal development programs and provide further long-term growth for the company."